Literature DB >> 26118369

Two Cases of Pathological Complete Response to Neoadjuvant Chemoradiation Therapy in Pancreatic Cancer.

Yoko Fujii-Nishimura1, Ryo Nishiyama, Minoru Kitago, Yohei Masugi, Akihisa Ueno, Koichi Aiura, Shigeyuki Kawachi, Miho Kawaida, Yuta Abe, Masahiro Shinoda, Osamu Itano, Akihiro Tanimoto, Michiie Sakamoto, Yuko Kitagawa.   

Abstract

Neoadjuvant chemoradiation therapy (NACRT) is increasingly used in patients with a potentially or borderline resectable pancreatic ductal adenocarcinoma (PDA) and it has been shown to improve survival and reduce locoregional metastatic disease. It is rare for patients with PDA to have a pathological complete response (pCR) to NACRT, but such patients reportedly have a good prognosis. We report the clinicopathological findings of two cases of pCR to NACRT in PDA. Both patients underwent pancreatectomy after NACRT (5-fluorouracil, mitomycin C, cisplatin, and radiation). Neither had residual invasive carcinoma and both showed extensive fibrotic regions with several ducts regarded as having pancreatic intraepithelial neoplasia 3/carcinoma in situ in their post-therapy specimens. It is noteworthy that both patients had a history of a second primary cancer. They both had comparatively good outcomes: one lived for 9 years after the initial pancreatectomy and the other is still alive without recurrence after 2 years.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26118369     DOI: 10.2302/kjm.2014-0014-CR

Source DB:  PubMed          Journal:  Keio J Med        ISSN: 0022-9717


  6 in total

1.  KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.

Authors:  Yutaka Nakano; Minoru Kitago; Sachiko Matsuda; Yuki Nakamura; Yusuke Fujita; Shunichi Imai; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Taizo Hibi; Yoko Fujii-Nishimura; Ayano Takeuchi; Yutaka Endo; Osamu Itano; Yuko Kitagawa
Journal:  Br J Cancer       Date:  2018-01-23       Impact factor: 7.640

2.  Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: a retrospective study.

Authors:  Yutaka Nakano; Minoru Kitago; Masahiro Shinoda; Yuta Abe; Hiroshi Yagi; Taizo Hibi; Ayano Takeuchi; Koichi Aiura; Osamu Itano; Yuko Kitagawa
Journal:  Cancer Med       Date:  2017-09-18       Impact factor: 4.452

3.  Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.

Authors:  Yutaka Endo; Minoru Kitago; Koichi Aiura; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Go Oshima; Shutaro Hori; Yutaka Nakano; Osamu Itano; Junichi Fukada; Yohei Masugi; Yuko Kitagawa
Journal:  World J Surg Oncol       Date:  2019-08-16       Impact factor: 2.754

4.  Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.

Authors:  Takahiro Yokose; Minoru Kitago; Sachiko Matsuda; Yasushi Sasaki; Yohei Masugi; Yuki Nakamura; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Go Oshima; Shutaro Hori; Fujita Yusuke; Yutaka Nakano; Yutaka Endo; Kodai Abe; Takashi Tokino; Yuko Kitagawa
Journal:  Cancer Sci       Date:  2020-05-30       Impact factor: 6.716

Review 5.  Peritoneal dissemination of pancreatic cancer caused by endoscopic ultrasound-guided fine needle aspiration: A case report and literature review.

Authors:  Hideaki Kojima; Minoru Kitago; Eisuke Iwasaki; Yohei Masugi; Yohji Matsusaka; Hiroshi Yagi; Yuta Abe; Yasushi Hasegawa; Shutaro Hori; Masayuki Tanaka; Yutaka Nakano; Yusuke Takemura; Seiichiro Fukuhara; Yoshiyuki Ohara; Michiie Sakamoto; Shigeo Okuda; Yuko Kitagawa
Journal:  World J Gastroenterol       Date:  2021-01-21       Impact factor: 5.742

6.  Usefulness of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for predicting the prognosis and treatment response of neoadjuvant therapy for pancreatic ductal adenocarcinoma.

Authors:  Takahiro Yokose; Minoru Kitago; Yohji Matsusaka; Yohei Masugi; Masahiro Shinoda; Hiroshi Yagi; Yuta Abe; Go Oshima; Shutaro Hori; Yutaka Endo; Kenji Toyama; Yu Iwabuchi; Ryo Takemura; Ryota Ishii; Tadaki Nakahara; Shigeo Okuda; Masahiro Jinzaki; Yuko Kitagawa
Journal:  Cancer Med       Date:  2020-04-12       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.